p38 MAP kinase alpha inhibitor (Xcovery)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namep38 MAP kinase alpha inhibitor (Xcovery)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTumor necrosis factor α inhibitorsInterleukin-1 modulatorsP38 α mitogen-activated protein kinase inhibitors
TargetsInterleukin-1Tumor necrosis factor αP38 α mitogen-activated protein kinase
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe Scripps Research Institute Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesXcoveryThe Scripps Research Institute Inc
Active IndicationsN/A
Inactive IndicationsInflammation

Other Information

ATC CodeN/A
Related LinksN/A